Naloxegol

Brand names: Movantik · Active ingredient: Naloxegol Oxalate

In short: MOVANTIK ® is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.

Forms & strengthsMOVANTIK (naloxegol) is available in two strengths: • Tablets: 12.5 mg supplied as mauve, oval, biconvex, film-coated, intagliated with “nGL” on one side and “12.5” on the other side. …
LabelAveritas Pharma, Inc.
Label updatedSep 02, 2026

What is Naloxegol used for?

MOVANTIK

® is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.

Naloxegol dosage

Discontinue all maintenance laxative therapy prior to initiation of MOVANTIK. Laxative(s) can be used as needed if there is a suboptimal response to MOVANTIK after three days.

Alteration in analgesic dosing regimen prior to initiating MOVANTIK is not required.

Patients receiving opioids for less than 4 weeks may be less responsive to MOVANTIK

.

Take MOVANTIK on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.

For patients who are unable to swallow the MOVANTIK tablet whole, the tablet can be crushed to a powder, mixed with 4 ounces (120 mL) of water, and drunk immediately. The glass should be refilled with 4 ounces (120 mL) of water, stirred and the contents drunk.

MOVANTIK can also be administered via a nasogastric (NG) tube, as follows:

1. Flush the NG tube with 1 ounce (30 mL) of water using a 60 mL syringe.

2. Crush the tablet to a powder in a container and mix with approximately 2 ounces (60 mL) of water.

3. Draw up the mixture using the 60 mL syringe and administer the syringe contents through the NG tube.

4. Add approximately 2 ounces (60 mL) of water to the same container used to prepare the dose of MOVANTIK.

5. Draw up the water using the same 60 mL syringe and use all the water to flush the NG tube and any remaining medicine from the NG tube into the stomach.

Avoid consumption of grapefruit or grapefruit juice during treatment with MOVANTIK.

Discontinue MOVANTIK if treatment with the opioid pain medication is also discontinued.

The recommended MOVANTIK dosage is 25 mg once daily in the morning. If patients are not able to tolerate MOVANTIK, reduce the dosage to 12.5 mg once daily

.

The starting dosage for patients with creatinine clearance (CLcr) <60 mL/min (i.e., patients with moderate, severe, or end-stage renal impairment) is 12.5 mg once daily. If this dosage is well tolerated but OIC symptoms continue, the dosage may be increased to 25 mg once daily taking into consideration the potential for markedly increased exposures in some patients with renal impairment and the increased risk of adverse reactions with higher exposures

.

Avoid concomitant use of MOVANTIK with moderate CYP3A4 inhibitor drugs (e.g., diltiazem, erythromycin, verapamil). If concurrent use is unavoidable, reduce the MOVANTIK dosage to 12.5 mg once daily and monitor for adverse reactions

.

How to take Naloxegol — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Administration

Advise patients to:

Discontinue all maintenance laxative therapy prior to initiation of MOVANTIK. Laxative(s) can be used as needed if there is a suboptimal response to MOVANTIK after three days.

Take MOVANTIK on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.

Discontinue MOVANTIK if treatment with the opioid pain medication is also discontinued.

Avoid consumption of grapefruit or grapefruit juice during treatment with MOVANTIK.

Inform their healthcare provider if their opioid pain medication is discontinued.

Inform their healthcare provider if they are unable to tolerate MOVANTIK, so a dosage adjustment can be considered.

If patients are unable to swallow the MOVANTIK tablet whole, the tablet can be crushed to a powder, mixed with water and administered orally or via a nasogastric (NG) tube, as described in the Medication Guide.

Drug Interactions

Advise patients to tell their healthcare provider when they start or stop taking any concomitant medications. …

Warnings & precautions

Do not take this medicine if: MOVANTIK is contraindicated in:

Patients with known or suspected gastrointestinal obstruction and patients at risk of recurrent obstruction, due to the potential for gastrointestinal perforation

.

Patients concomitantly using strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) because these medications can significantly increase exposure to naloxegol which may precipitate opioid withdrawal symptoms such as hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning

.

Patients who have had a known serious or severe hypersensitivity reaction to MOVANTIK or any of its excipients

.

Clusters of symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning have occurred in patients treated with MOVANTIK

. In addition, patients receiving methadone as therapy for their pain condition were observed in clinical trials to have a higher frequency of gastrointestinal adverse reactions that may have been related to opioid withdrawal than patients receiving other opioids

. Patients having disruptions to the blood-brain barrier may be at increased risk for opioid withdrawal or reduced analgesia. Take into account the overall risk-benefit profile when using MOVANTIK in such patients. Monitor for symptoms of opioid withdrawal in such patients.

Reports of severe abdominal pain and/or diarrhea have been reported, some of which resulted in hospitalization. Most of the cases of severe abdominal pain were reported in patients taking the 25 mg dosage. Symptoms generally occurred within a few days of initiation of MOVANTIK. Monitor patients for the development of abdominal pain and/or diarrhea with MOVANTIK and discontinue therapy if severe symptoms occur. Consider restarting MOVANTIK at 12.5 mg once daily, if appropriate. …

Naloxegol side effects

Serious and important adverse reactions described elsewhere in labeling include:

Opioid withdrawal

Severe abdominal pain and/or diarrhea

Gastrointestinal perforation

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described below reflect exposure to MOVANTIK in 1497 patients in clinical trials, including 537 patients exposed for greater than six months, and 320 patients exposed for 12 months.

The safety data described in Table 1 are derived from two double-blind, placebo-controlled trials (Studies 1 and 2) in patients with OIC and non-cancer related pain

. Study 3 (n=302) was a safety extension study that allowed patients from Study 1 to continue the same blinded treatment for an additional 12 weeks. Safety data for patients in Study 3 are similar to those listed in Table 1. Study 4 (n=844) was a Phase 3, 52-week, multi-center, open-label, randomized, parallel group, safety and tolerability study of naloxegol versus usual care treatment for OIC (as determined by the investigator and excluding peripheral opioid antagonists) in patients with non-cancer related pain. The population enrolled in Study 4 was similar to that of the other studies. …

Drug interactions

Table 2 displays the effects of other drugs on MOVANTIK.

Concomitant Agent | Mechanism of Action | Clinical Recommendation

CYP3A4 Inhibitors

•Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) | •Increase plasma naloxegol concentrations and may increase the risk of adverse reactions

. | •Use with strong CYP3A4 inhibitors is contraindicated

.

•Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil) | •Avoid use with moderate CYP3A4 inhibitors; if unavoidable, decrease the dosage of MOVANTIK to 12.5 mg once daily and monitor for adverse reactions

.

•Weak CYP3A4 inhibitors (e.g., quinidine, cimetidine) | •Clinically significant increases in naloxegol concentrations are not expected. | •No dosage adjustments are necessary.

•Grapefruit or grapefruit juice

The effect of grapefruit juice varies widely among brands and is concentration-, dose-, and preparation-dependent. Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation was used (e.g., high dose, double strength) or as a “moderate CYP3A inhibitor” when another preparation was used (e.g., low dose, single strength). | •Can increase plasma naloxegol concentrations. …

About this medicine

MOVANTIK (naloxegol), an opioid antagonist, contains naloxegol oxalate as the active ingredient. (Naloxegol is a PEGylated derivative of naloxone.)

The chemical name for naloxegol oxalate is: (5α,6α)-17-allyl-6-(2,5,8,11,14,17,20-heptaoxadocosan-22-yloxy)-4,5-epoxymorphinan-3,14-diol oxalate. The structural formula is:

The empirical formula for naloxegol oxalate is C

34H

53NO

11.C

2H

2O

4and the molecular weight is 742.

Naloxegol oxalate is a white to off-white powder, with high aqueous solubility across the physiologic pH range.

MOVANTIK (naloxegol) tablets for oral use contain 14.2 mg and 28.5 mg of naloxegol oxalate, respectively, equivalent to 12.5 mg and 25 mg of naloxegol.

Excipients in tablet core are: mannitol, cellulose microcrystalline, croscarmellose sodium, magnesium stearate, and propyl gallate.

Excipients in tablet coat are: hypromellose, titanium dioxide, polyethylene glycol, iron oxide red, and iron oxide black.

How it works: Naloxegol is an antagonist of opioid binding at the mu-opioid receptor. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 28596788-b73f-4247-85fc-3105f51fff5a. Read the full official label on DailyMed.

Related medicines

Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine